Insulin action and insulin specific binding to erythrocytes were examined in ten recipients of a pancreatic segment and renal graft (Group 1), in nine non-diabetic kidney recipients (Group 2) and in ten age-and weightmatched healthy control subjects (Group 3). All transplant recipients were normoglycaemic without need of insulin, received the same immunosuppression and had good renal graft function at 11-18 months post-transplantation, when the investigation was performed. Using the insulin clamp technique, insulin action was expressed as the metabolic clearance rate of glucose at insulin infusion rates of 1.0 (MCRsubmax) and 10.0 (MCRmax) mU.kg-l.min -I. In comparison with the healthy control subjects, fasting free insulin and C-peptide levels were significantly higher in Groups 1 and 2, but no differences between Groups 1 and 2 were found (p>0.05).
Introduction
It is generally accepted that systemic insulin delivery accounts for elevated insulin levels after successful pancreas transplantation (van Goor et al. 1986; Nason et al. 1988; Lugagne et al. 1989; van der Burg et al. 1989; Diem et al. 1990 ). An additional cause of hyperinsulinaemia might be insulin resistance. The present study was therefore designed to examine whether insulin action in recipients of pancreas and kidney differs from that in healthy subjects and if it does, whether the difference is related to immunosuppressive therapy or to the presence of the pancreatic graft. In order to differentiate a possible receptor or post-receptor defect in insulin action, we used the hyperinsulinaemic clamp method at two insulin infusion rates and we determined the insulin binding to its receptors on erythrocytes.
Subjects and methods

Subjects. Insulin action and receptor binding was studied in ten
Type 1 (insulin-dependent) diabetic patients with end-stage diabetic nephropathy at 11-18 months post-successful pancreas and kidney transplantation (Group 1), in nine non-diabetic kidney recipients at 11-14 months post-transplantation (Group 2)and in ten age-and weight-matched healthy control subjects (Group 3). The purpose, nature and potential risks of the study were explained to all the subjects and written consent was obtained before their participation. The characteristics of each group are listed in Table  1 . In Group 1, together with the kidney, a pancreatic segment was transplanted whose splenic artery had been anastomosed to iliac arteries. The splenic vein of the graft was anastomosed to iliac veins. The pancreatic duct was occluded by prolamine. All the transplant recipients were normoglycaemic and did not require exogenous insulin. The highest glycaemia on the day preceding the investigation was 7.5 retool/1 lh postprandially. Immunosuppressive therapy was the same in Groups 1 and 2 and consisted of prednisone (10 mg per day), cyclospofine A (trough 
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NP = not performed
blood levels 300-600 ng/ml by non-specific RIA) and azathioprine (50-75 mg per day). All transplant recipients showed stable good function of the renal graft at the time of the study. None had been treated for a rejection episode during the previous 6 months.
Insulin clamp ~tudy. Insulin action was measured by the euglyeaemic clamp technique (DeFronzo et al. 1979) . Before the study, a catheter was inserted into an antecubital vein for glucose and insulin administration. To ensure arterialization of the blood, a second catheter for blood sampling was inserted in most transplant recipients into the arteriovenous fistula, which had been employed as an access for haemodialysis in the pre-transplant period. In four recipients and in all the healthy subjects the second catheter was placed into a forearm vein and the hand was then inserted into a heated box that was maintained at 65oc. Crystalline porcine insulin was administered over two consecutive 90-rain periods. Each infusion was begun at a high rate and followed by an exponential declining, analogically to the method of DeFronzo et al. (1979) , before achieving a constant rate of 1.0 and 10.0 mU'kg'l'min "1 after I0 min. Glyeaemia was maintained at 5.0 mmol]l with a coefficient of variation up to 6.0%. As a measure of insulin action the submaximal and maximal metabolic clearance rate of glucose (MCRsubmax and MCRrnax ) calculated during the last 30 rain of each 90-rain period was used. The metabolic clearance rate of glucose was calculated by dividing the glucose utilization rate, determined according to DeFronzo et al. (1979) , by the mean glucose concentration during the study (Gottesman et al. 1984) . Serum free insulin (IRI), C-peptide and glycaemia were measured on two consecutive days in the fasting state. Postprandial glycaemia was measured lh after ingestion of mixed meal containing 60g carbohydrate. Glucose disappearance constant (KG) was measured after administration of 0.338 glucose/kg intravenously. Glyeaemia was measured from 10-60 min and IRI and C-peptide were measured at times 0,4,15,30 and 60 rain following glucose administration. The area under the curve of insulin and C-peptide concentration (AUC I and AUCcp ) was calculated.
Analytical methods. Blood glucose was measured by the glueoseoxidase method on a Beckman Analyzer. HbAIC was determined colorimetrically (Standefer et al. 1984) . IRI was assessed by RIA after treatment with polyethylene glycol to remove insulin antibodies (Nagakawa et al. 1973 ) using kits manufactured by the Institute of Atomic Energy (Swierk, Poland). C-peptide was determined by RIA using kits from Serono diagnostics, S.A. (Switzerland).
Insulin binding. Insulin binding to erythrocytes was measured
according to a modification of the method of Garnbhir et al. (1978) . Erythroeytes were incubated in qiaadruplicate (400 ul) with 0. Mean levels of fasting IRI and C-pepfide, AUC I and AUCcp during the intravenous glucose tolerance test are shown in Table 2 . As compared with IRI in healthy control subjects, the parameter was elevated in Group 2 (p<0.01) as well as in Group 1 (9<0.05). Fasting Cpeptide levels were also elevated in both transplant groups (p<0.05). However, no statistical differences were found between the two groups of transplant recipients in fasting IRI and C-peptide levels (9>0.05). During the intravenous glucose tolerance test, significantly larger AUC I (p<0.01) and AUCcp (p<0.05) were demonstrated in pancreas graft recipients than in healthy control subjects.
The results of glycaemic clamp studies at both insulin infusion rates are shown in Figure 1 . Compared with control subjects both groups of transplant recipients show significantly reduced MCRsubmax (p<0.05), and MCRma x (Group 1 vs Group 3 p<0.01, Group 2 vs Group 3 p<0.05). There is no difference between both groups of transplant recipients (9>0.05). Table 2 . No statistically significant differences were found in the binding data. (9>0.05).
Discussion
While a technical fault is the leading cause of pancreas graft failure in the early post-transplant period, later on, rejection and other reasons, not yet sufficiently established, are more prominent. Just as in non-diabetic subjects, glucose tolerance of pancreas graft recipients depends on two major determinants: Beta-cell function and insulin action. A defect of each may contribute to the reappearance of diabetic disturbance.
In this study we have examined the insulin action in two groups of transplant recipients which were comparable as regards age, BMI, time after transplant, immunosuppression and renal graft function.
In comparison with healthy subjects, we demonstrated a significant decrease in the metabolic clearance rate of glucose in both groups of transplant recipients. No differences in insulin action between the two groups of recipients were found. The mean metabolic clearance rates were reduced by approximately 40% at an insulin infusion rate of 1.0 mU.min'l'kg -1 and by approximately 35% at an insulin infusion rate of 10 mU/min. Fasting IRI and Cpeptide levels were also not different between the two groups of recipients and were more than doubled in comparison with those in healthy subjects. The method of blood collection was not fully standardised in our clamp studies. Because of poor venous access, arterio-venous fistulas were used in most transplant recipients, while in control subjects blood from the hand lying in a heated box was collected. However, the differences in metabolic clearance rates of glucose between the control subjects and both the transplant groups were too high to be explained by better arterialization in transplant recipients. Thus, the results indicate that insulin action is impaired in both groups of transplant recipients and that insulin resistance is roughly of the same degree. The decreased submaximal as well as maximal responses to insulin tend to suggest mainly a post-receptor defect in insulin action (Kahn 1978) . In addition, no significant receptor defect was found by examination of insulin specific binding to erythrocytes. However, erythrocytes are not insulin sensitive and examination of insulin binding to other tissues would be necessary to confirm our fmdings.
The main cause of insulin resistance following kidney transplantation is probably corticosteroid administration, although the effect of cyclosporine has also been suggested by some (Yale et al. 1988; Ost et al. 1988; Waldstrom et al. 1990) but not proved by all investigators (Dresner et al. 1989) . Rizza et al. (1982) demonstrated that 24-h infusion of cortisol in healthy subjects significantly impaired inhibition of hepatic glucose production and stimulation of glucose utilization by insulin. The decreased insulin action at the maximal insulin infusion rate and no changes in insulin binding suggested a corticosteroid-induced postreceptor defect, as in our study. On the contrary, other authors found decreased insulin binding to erythrocytes (Yasuda et al. 1980) or monocytes (DePirro et al. 1980) induced by glucocorticoids. Ekstrand et al. (1989) demonstrated a 25% reduction in total glucose disposal in non-diabetic kidney recipients receiving an average of 8.2 mg prednisolone per day in comparison with healthy control subjects.
Insulin resistance following pancreas transplantation should have a similar cause as in non-diabetic kidney recipients, since most transplanted subjects are on a similar immunosuppressive regimen. However, this has not yet been clearly documented. Luzi et al. (1990) recently investigated insulin sensitivity after successful pancreatic grafting at insulin infusion rates corresponding approximately to the low one in our study. Although they found insulin resistance when compared with healthy control subjects, the control group of non-diabetic recipients was too small to draw convincing conclusions. Moreover, insulin resistance could also consist in other reasons. In fact, it is a feature characteristic of Type 1 diabetes (DeFronzo et al. 1982) and may be related to the degree of glucose tolerance. Although all recipients in Group 1 fulfilled the criteria of "full function of the pancreatic graft", their KG values were significantly lower than in the healthy control subjects. Nevertheless, the three subjects of Group 1 with KG values between 0.7 and 0.98%/min had the values of MCRsubmax 5. 45, 7.46, and 9.08 and of MCRmax12.45, 14.44, and 15 .65 ml'kg" 1.min-1 which all are lying only slightly below, or even above the mean values of the whole Group 1. Since peripheral hyperinsulinaemia per se is able to induce insulin resistance (Marangou et al. 1986) , it could be a consequence of the heterotopic placement of the pancreatic graft. Recently, Diem et al. (1990) demonstrated basal and stimulated hyperinsulinaemia but normal C-peptide production in recipients of pancreatic graft with systemic venous drainage as compared with non-diabetic kidney recipients and healthy subjects. They conclude that hyperinsulinaemia following pancreas transplantation is mainly due to systemic insulin delivery.
While in non-diabetic kidney recipients insulin resistance is a frequent cause of secondary diabetes mellitus, in pancreas graft recipients, because of increased demands, the surviving Beta cells may not be able to secrete sufficient insulin to maintain normal glucose tolerance. A relative defect of Beta-cell function is probable in most recipients with a functioning pancreatic graft, since the Beta-cell mass may be reduced by many factors, such as conservation, ischaemia, rejection, fibrosis and size of the graft. In addition, insulin secretion may be suppressed by cyclosporine A (Dresner et a1.1989; Gillison et al. 1989; Alejandro et a1.1989) . In spite of that, most recipients with functioning grafts have basal and meal-or glucosestimulated hyperinsulinaemia which may be preserved even in the case of impaired glucose tolerance or recurrence of the diabetic state (Smith et al. 1989) . We conclude that the immunosuppressive therapy currently used in pancreas transplantation induces insulin resistance, which may be at least partially responsible for the elevated insulin levels. It is probable that substitution of glucocorticoids by another immtmosnppressive drug with a less pronounced diabetogenic effect could improve overall results of pancreas transplantation. 
